Lead

Farmaceutski Fakultet Universitetau Beogradu
Faculty of Pharmacy
Prof Marin Jukic

Co-Lead

Universitätsklinikum Bonn
Institute of Human Genetics
Prof. Markus Nöthen

Participants/Support

• Karolinska Institute
• Parnassia Groep BV
  

Goals

• Establish logistics for sample collection, processing, storage and shipment at the clinical centres as well as effective communication between clinical centres and central facilities
• Building of the PSY-PGx DNA biobank
• Development of the PSY-PGx cellular biobank
• Perform genotyping for common genetic variants throughout the clinical trial
• Perform retrospective therapeutic drug level quantification
• Interpretation of the results obtained in collaboration with WP5 (Clinical Study)
  

Lead

Fundació Clínic per la Recerca Biomédica
Department of Psychiatry & Psychology
Prof. Eduard Vieta

Co-Lead

University Maastricht
Department of Psychiatry and Neuropsychology
Prof. Thérèrese van Amelsvoort

Participants/Support

• King's College London
• Global Alliance of Mental Illness Advocacy Networks
• Fundació Clínic per la Recerca Biomédica
• SUNY Upstate Medical University
• Universitätsklinikum Bonn
  

Goals

• Maintain an stringent strategy for clinical data collection
• Finalize the Clinical Study Document
• Monitoring and site visits
• Quality control
• Set-up training for clinical staff and patients
  

Lead

Rijksuniversiteit Groningen
Groningen Institute of Evolutionary Life Science & Engineering (BEHAPP)
Prof. Martien Kas

Co-Lead

Tel Aviv University
Sackler Faculty of Medicine
Prof. Noam Shomron

Participants/Support

• Parnassia Groep BV
• Rijksuniversiteit Groningen

Goals

Prepare the IT foundation for the clinical trial to support the phenotyping of patients during the clinical study via apps.

Lead

Universitatea Babeş-Bolyai
Department of Psychology
Dr. Ramona Moldovan

Co-Lead

Ludwig-Maximilians-Universität München
Institute of Psychiatric Phenomics and Genomics
PD Dr. Urs Heilbronner

Participants/Support

• Global Alliance of Mental Illness Advocacy Networks
• 
World Psychiatric Association

• Parnassia Groep BV

Goals

• Define the project security policy and assess the implications and impact on different factors (ethical, psychosocial and economic) that will determine the future adoption of the PSY- PGx approach.
• Provide reliable information to stakeholders within different healthcare systems across Europe and beyond.

Lead

Parnassia Groep BV
Department of Psychiatry
Ass. Prof. Roos van Westrhenen

Co-Lead

University Maastricht
Department of Psychiatry and Neuropsychology
Prof. Koen Schruers

Participants/Support

• Rijksuniversiteit Groningen
• Tel Aviv University
• All clinical sites

Goals

• Use CASTOR to provide a sustainable data infrastructure relying on a powerful IT framework adhering to the highest standards of data protection
• Adhere to the FAIR Guiding Principles for scientific data management and stewardship (findability, accessibility, interoperability, reusability)
• Design and maintain a stringent strategy to support the work of the consortium by setting up a consortium-stakeholder network, drawing from the diversity of the disciplines involved.

Lead

Helsinki University
Institute for Molecuar Medicine Finland FIMM & Department of Public Health
Prof. Jaakko Kaprio

Co-Lead

King’s College London
Institute of Psychiatry, Psychology & Neurosciences
Prof. Allan Young and Dr. Mario Juruena

Participants/Support

• Tel Aviv University

Goals

Big data will be obtained from Finnish and UK genetic databases to assess pharmacogenetic genotype and clinical outcomes in patients with mood-, anxiety or psychotic disorders to investigate real-world, large-scale and long-term perspectives on outcomes of specific disease – medication stratified by CYP2C19 and CYP2D6 genotype.

Lead

Co-Lead

Universitätsklinikum Bonn
Klinik für Psychiatrie und Psychotherapie
Prof. Alexandra Philipsen

Participants/Support

• All clinical centers
• Rijksuniversiteit Groningen

Goals

• Conduct the 24-week randomized, patient- and rater-blind, two-arm, parallel-group controlled trial of pharmacogenetics-informed pharmacotherapy in 9 centers across 7 European countries and the US. This will be done in n=2500 patients starting or alternating psychopharmacotherapy for mood disorders (group 1, n=1250), anxiety disorders (group 2, n=750), and psychotic disorders (group 3, n=500).
• Big data will be obtained from Finnish and UK genetic databases to assess pharmacogenetic genotype and clinical outcomes in patients with mood-, anxiety or psychotic disorders to investigate real-world, large-scale and long-term perspectives on outcomes of specific disease – medication stratified by CYP2C19 and CYP2D6 genotype.

Lead

Tel Aviv University
Sackler Faculty of Medicine
Prof. Noam Shomron

Co-Lead

Parnassia Groep BV
Department of Psychiatry
Ass. Prof. Roos van Westrhenen

Participants/Support

• Helsinki University
• Rijksuniversiteit Groningen

Goals

Develop an algorithm with data from the Biobanks from WP4 and the Clinical Trial in WP5

Lead

Ludwig-Maximilians-Universität München
Institute of Psychiatric Phenomics and Genomics
PD Dr. Urs Heilbronner

Co-Lead

SUNY Upstate Medical University
Department of Psychiatry
Prof. Thomas G. Schulze

Participants/Support

• Global Alliance of Mental Illness Advocacy Networks
• World Psychiatric Association
• Parnassia Groep BV

Goals

• Raise awareness of PSY-PGx
• Involve stakeholders throughout the project
• Communicate, disseminate and exploit the results achieved adhering to Open Science principles

Lead

Parnassia Groep BV
Department of Psychiatry
Ass. Prof. Roos van Westrhenen

Co-Lead

Universiteit Maastricht
Department of Psychiatry and Neuropsychology
Prof. Bart Rutten

Participants/Support

• Universitatea Babeş-Bolyai
• World Psychiatric Association
• Ludwig-Maximilians-Universität München

Goals

Facilitate the successful completion of the project